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In acute lymphoblastic leukaemia, MLPA has been used in research studies to identify clinically relevant 
copy number abnormality (CNA) profiles. However, in diagnostic settings other techniques are often 
employed. We assess whether equivalent CNA profiles are called using SNP arrays, ensuring platform 
independence. We demonstrate concordance between SNP6.0 and MLPA CNA calling on 143 leukaemia 
samples from two UK trials; comparing 1,287 calls within eight genes and a region. The techniques are 
99% concordant using manually augmented calling, and 98% concordant using an automated pipeline. 
We classify these discordant calls and examine reasons for discordance. In nine cases the circular binary 
segmentation (CBS) algorithm failed to detect focal abnormalities or those flanking gaps in IKZF1 
probe coverage. Eight cases were discordant due to probe design differences, with focal abnormalities 
detectable using one technique not observable by the other. Risk classification using manually 
augmented array calling resulted in four out of 143 patients being assigned to a different CNA risk group 
and eight patients using the automated pipeline. We conclude that MLPA defined CNA profiles can be 
accurately mirrored by SNP6.0 or similar array platforms. Automated calling using the CBS algorithm 
proved successful, except for IKZF1 which should be manually inspected.
B-cell precursor acute lymphoblastic leukaemia (B-ALL) arises from the accumulation of immature cells within 
the bone marrow and blood, and is characterised by key chromosomal and genetic abnormalities1. Accurate risk 
stratification of B-ALL is essential for assignment of patients to appropriate treatment regimens, balancing the 
efficacy of treatment with the cytotoxic nature of the chemotherapeutic agents. B-ALL cases are risk stratified into 
high, low and intermediate risk, on the basis of primary genomic abnormalities, which are routinely detected by 
techniques such as karyotyping and fluorescence in situ hybridization (FISH)2. However, approximately 25% of 
patients with B-ALL lack the common primary chromosomal abnormalities. This group, termed B-other-ALL, 
are classed as intermediate risk, as indicated in the paediatric treatment trial, UKALL97/993. Within this sub-
group, there is a clinical need to identify genetic biomarkers to enable risk stratification. Current risk stratification 
algorithms use a combination of age, white cell count (WCC), minimal residual disease (MRD) and chromosomal 
abnormalities. Novel risk stratification algorithms have been developed that incorporate copy number abnormal-
ities (CNAs), including gains, amplifications, losses, and deletions of specific genes or genomic regions, including 
sets of genes4. These algorithms will be used alongside established risk factors to stratify patients in upcom-
ing European trials for ALL; AIEOP-BFM ALL 20175 and ALLTogether6. Both the UKALL-CNA4 profile and 
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IKZF1plus 7 were developed using copy number data generated by Multiplex Ligation-Depend Probe Amplification 
(MLPA). MLPA is a multiplexed PCR assay that uses probes specific for exons within genes of interest, enabling 
the relative copy number of each covered exon to be reported as a ratio against other probe(s) within reference 
regions. In addition, MLPA has been used to assist the molecular diagnosis of a wide variety of diseases8. SNP 
arrays are also used for detection of CNAs with several advantages: detection of CNAs involving all genes rather 
than a defined set, other clinically relevant events such as aneuploidy, ploidy changes or partial chromosomal 
imbalances can also be detected. From a clinical diagnostic laboratory perspective, SNP arrays provide a useful 
real-time technique, they are genome wide and not disease-specific such as most MLPA kits. Thus, many diag-
nostic laboratories frequently have SNP array platforms in place for other cancer work or constitutional genet-
ics. While previous studies have compared MLPA and SNP array copy number concordance, they have either 
focussed on single genes or have been applied to the analysis of germline DNA; neither of which are relevant 
to validation of the UKALL-CNA classifier. In B-ALL specifically, Dörge et al. investigated concordance among 
25 ALL patients for IKZF1 abnormalities. They found 23 known IKZF1 deletions detected by SNP6.0 array also 
to be detectable by MLPA, with minor differences at exon level due to probe positioning9. In addition, Zanardo 
et al. investigated a cohort of 93 patients with developmental and congenital abnormalities, using MLPA and 
SNP arrays and showed a 98% concordance between the two techniques10. To our knowledge, there has been no 
large-scale systematic study investigating the comparative performance of CNA detection using SNP array and 
MLPA techniques for an established set of key prognostic genes and genomic regions in leukaemia.
It is important to validate biomarkers using different techniques as well as different patient cohorts. The 
UKALL-CNA and the IKZF1plus profiles have been validated across different patient populations. In this study, we 
validate the use of SNP arrays for detection of key CNAs, which underpin these two copy number profiles in ALL. 
In addition, we sought to compare the performance of the two techniques in order to assess both the concordance 
of SNP6.0 arrays and MLPA, as well as the ability of automated SNP array analysis to call CNAs.
Methods
Cohort and classification criteria. Patients were diagnosed with B-cell precursor ALL by standard 
flow-cytometric criteria and were treated on Medical Research Council (MRC) ALL97/99 (1997–2002) or United 
Kingdom UKALL2003 (2003–2011). Full details of these treatment regimens have been previously published11,12. 
Local ethical committee approval was obtained for ALL97 by individual treatment centres, whereas approval for 
UKALL2003 was obtained from the Scottish Multi-Centre Research Ethics Committee. Informed consent was 
given by parents and patients in accordance with the Declaration of Helsinki. Briefly, in ALL99 and UKALL2003, 
patients were assigned to regimen A or B based on whether they were National Cancer Institute (NCI) standard 
(<10 years old and WCC < 50 × 109/L) or high risk (≥10 years old or WCC ≥ 50 × 109/L), respectively.
Cytogenetic and FISH testing was performed on pre-treatment bone marrow samples by member laboratories 
of the UK Cancer Cytogenetics Group or centrally by the Leukaemia Research Cytogenetics Group, and results 
were reported using established nomenclature and definitions3. Patients with absence of the following chromo-
somal abnormalities: ETV6-RUNX1, high hyperdiploidy (51–65 chromosomes), BCR-ABL1, KMT2A/MLL rear-
rangements, near haploidy (<30 chromosomes), low hypodiploidy (30–39 chromosomes), intrachromosomal 
amplification of chromosome 21 (iAMP21) or TCF3-HLF; were classified as B-other-ALL and were included in 
this study.
IKZF1 ETV6 CDKN2A
Normal Abnormal Normal Abnormal Normal Abnormal
MLPA
SNP
Normal 113 1 iv Normal 120 1 iv Normal 83 3 i
Abnormal 0 21, 8 iii Abnormal 0 22 Abnormal 0 57
CDKN2B RB1 BTG1
Normal Abnormal Normal Abnormal Normal Abnormal
Normal 83 2 ii Normal 131 2 iv Normal 142 0
Abnormal 0 58 Abnormal 0 10 Abnormal 0 1
EBF1 PAX5 PAR1
Normal Abnormal Normal Abnormal Normal Abnormal
Normal 133 0 Normal 95 2 iv Normal 138 2 i
Abnormal 1 v 9 Abnormal 2 v 43, 1 iii Abnormal 0 3
Table 1. Concordance between SNP array and MLPA data. This shows the nature of the concordant and 
discordant calls for each of the eight genes and the PAR1 region. Disagreement categories are shown as roman 
numerals. i = no SNP array probes covering the abnormality– meaning that due to the array design it is 
impossible to make a call. ii = MLPA result was informed by a single MLPA probe. iii = The CBS algorithm 
failed to pick up a small focal abnormality, which could be called visually by inspection of the Log R Ratio 
(LRR) data such that they would be concordant with the MLPA calls. iv = The two techniques disagree despite 
sufficient probe coverage. v = SNP6.0 detected an abnormality which could not be detected by MLPA due to 
lack of probe coverage.
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Array normalisation and copy number calling. DNA was hybridised to Affymetrix SNP6.0 arrays 
by AROS Applied Biotechnology A/S, Denmark. Data from array hybridisation was received as CEL files. 
PennCNV-Affy13 was used to perform quantile normalisation and calculate Log R ratio (LRR) data using HapMap 
reference clusters. This enabled all 1.8 million probes on a SNP6.0 array to be used; both copy number and SNP 
probes. The LRR data was GC content corrected for hg19 using PennCNV14. LRR data was then loaded in the R 
statistical computing environment15 and copy number segmentation was performed using the binary segmen-
tation algorithm (CBS) implemented in the DNACopy16,17 package in Bioconductor18. An overview of the copy 
number pipeline is given in Supplementary Fig. S1. Full details of the automated copy number calling are given in 
the on-line supplemental methods sections.
MLPA. MLPA was performed on DNA extracted directly from pre-treatment bone marrow samples, all sam-
ples had >90% blasts, sample handling and processing of cells was as previously described in Schwab et al.19. The 
same DNA source was used for MLPA and SNP6.0. The SALSA MLPA kit P335 (MRC Holland, Amsterdam, 
The Netherlands), which includes probes for IKZF1, CDKN2A/B, PAX5, EBF1, ETV6, BTG1, RB1, and the PAR1 
region, was used to identify CNAs involving these genes20. Previous studies have demonstrated that MLPA can 
accurately detect deletions within each of these genes when present in 20% or more cells19,20. A detailed descrip-
tion and breakdown of each CNA and the correlation with specific chromosomal abnormalities for all the patients 
within these two cohorts has been previously published20. MLPA data analysis methodology and peak ratio values 
used to make MLPA calls are as previously described in Schwab et al.19.
Gene/
Region
Patient 
ID CNA-MLPA
CNA-
SNP6.0: 
CBS
CNA-SNP6.0: 
manual
Discordance 
type
UKALL-
CNA: 
MLPA
UKALL-
CNA: SNP-
CBS
UKALL-
CNA: SNP-
manual
IKZF1 19732 deletion ex4-7 normal deletion ex4-7 iii IR/PR IR/PR IR/PR
IKZF1 20035 deletion ex2-7 normal deletion ex2-7 iii IR/PR GR IR/PR
IKZF1 20753 deletion ex4-8 normal deletion ex4-8 iii IR/PR IR/PR IR/PR
IKZF1 22964 deletion ex4-7 normal deletion ex4-7 iii IR/PR IR/PR IR/PR
IKZF1 22388 deletion ex4-7 normal deletion ex4-8 iii IR/PR GR IR/PR
IKZF1 10054 deletion ex4-7 normal deletion ex4-7 iii IR/PR GR IR/PR
IKZF1 10062 deletion ex4-7 normal deletion ex4-8 iii IR/PR IR/PR IR/PR
IKZF1 11560 deletion ex4-7 normal — iv IR/PR GR GR
IKZF1 11741 deletion ex4-7 normal deletion ex4-7 iii IR/PR GR IR/PR
ETV6 8947 deletion normal — iv IR/PR IR/PR IR/PR
CDKN2A 20753 deletion normal — i IR/PR IR/PR IR/PR
CDKN2A 22572 deletion normal — i IR/PR GR GR
CDKN2A 22689 deletion normal — i IR/PR IR/PR IR/PR
CDKN2B 21324 deletion normal — ii IR/PR IR/PR IR/PR
CDKN2B 22572 deletion normal — ii IR/PR GR GR
RB1 10958 deletion normal — iv IR/PR GR GR
RB1 20874 gain normal — iv IR/PR IR/PR IR/PR
EBF1 3278 normal loss — v IR/PR IR/PR IR/PR
PAX5 9262 gain normal — iv IR/PR IR/PR IR/PR
PAX5 10077 gain normal gain iii GR GR GR
PAX5 10442 gain normal† — iv IR/PR IR/PR IR/PR
PAX5 20515 normal loss — v GR GR GR
PAX5 11957 normal loss — v GR GR GR
PAR1 11403 rearrangement normal — i IR/PR GR GR
PAR1 21819 rearrangement normal — i IR/PR IR/PR IR/PR
Table 2. Full table of results broken down by patient ID including the nature of IKZF1 discordance. Most 
IKZF1 cases have an exon 4 to 7 loss, these are much harder for the circular binary segmentation (CBS) 
algorithm to detect because of the occurrence of them after a gap in coverage of a covered region. The UKALL-
CNA-SNP6.0 CBS column gives the calls from the automated CBS algorithm in DNACopy. The entries in the 
UKALL-CNA-SNP6.0 manual column give the result from manual calling of events using the Log R Ratio 
(LRR) plots, only cases where the call changes to that of the UKALL-CBS-SNP6.0 column are shown, in cases 
where the call remained the same - is recorded. Only one of the cases had a spanning deletion of exons 2–7. The 
classification of the nature of dis/concordance is as in Table 1. i = no SNP array probes covering the abnormality 
- meaning that due to the array design it is impossible to make a call. ii = MLPA result was informed by a single 
MLPA probe. iii = The CBS algorithm failed to pick up a small focal abnormality, which could be called visually 
by inspection of the LRR data such that they would be concordant with the MLPA calls. iv = The two techniques 
disagree despite sufficient probe coverage. In one of these six cases of disagreement FISH data was available and 
validated the normal calls made by SNP6.0 this is indicated by †. v = SNP6.0 detected an abnormality which 
could not be detected by MLPA due to lack of probe coverage.
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Figure 1. Examples of concordant and discordant calls by the SNP6.0 pipeline and MLPA. Patient ID and gene 
name, along with disagreement category in parenthesises are shown in the title of each plot. Individual SNP6.0 
data points of Log R Ratio (LRR) are shown in grey, copy number calls by the binary segmentation algorithm 
are shown as black lines, with the copy normal LRR value of zero shown as a grey dotted line. Exons from genes 
are plotted as plotted boxes in rainbow colour, and MLPA data points converted into the LRR scale are shown 
as stars. (A) Shows a concordant Abnormal-Abnormal EBF1 call. (B) Shows an example of a case in which 
limited coverage by MLPA misses a focal abnormality in EBF1 exons 1 to 6, here the sole MLPA probe reports 
a slight gain but without further probes until exons 10, 14, and 16, this focal abnormality detected by SNP6.0 
is missed in MLPA. (C) A highly focal abnormality occurring in IKZF1 which was manually observed but the 
binary segmentation (CBS) algorithm failed to identify. The abnormality is very focal and flanks a region of the 
IKZF1 gene where there is no probe coverage between IKZF1 exons 3 and 4 (“IKZF1 hole”). (D) A highly focal 
loss within CDKN2A is picked up by MLPA but is undetected by SNP6.0 array as no probes lie within CDKN2A. 
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Copy number call comparison. Discordant calls between MLPA and the automated array pipeline were 
extracted from both datasets, each discordant call was manually inspected by three independent reviewers (MB, 
RH, AE) by visualising the LRR data for the gene of interest. This approach also permitted manual calling of focal 
events that were discernible by eye in the LRR plots but missed using the CBS algorithm. Joint manual review was 
undertaken to determine the nature and likely cause of discordance.
For the purpose of this study, we have considered losses/deletions and gains/amplifications, as the same event 
owing to the use of different copy number thresholds and sensitivities between SNP6.0 and MLPA. Additionally, 
as no formal definition or threshold for copy number gain versus amplification and similarly loss versus deletion 
exist, we have chosen to aggregate these two pairs of events in to either gain/amplification or loss/deletion.
Details of MLPA probe location determination methodology and representativeness of our cohort is given in 
the on-line supplemental methods section.
Results
Concordance of copy number abnormality calls. We compared the copy number calls from MLPA 
and our SNP array pipeline for 143 diagnostic samples from B-other-ALL patients treated on ALL97–99 or 
UKALL2003. The demographics of these patients are detailed in Supplementary Tables S1 and S2. Specifically, 
we compared the genes included in the P335-MLPA kit used in the UKALL-CNA classifier: IKZF1, CDKN2A/B, 
PAX5, EBF1, ETV6, BTG1, RB1, and the PAR1 region (CRLF2/CSF2RA/IL3RA)4.
Using the value of copy returned by the CBS algorithm, we found 98% of the calls to be concordant between 
the SNP6.0 pipeline and MLPA, with 25 calls discordant out of a total of 1,287 (Table 1). Manual event calling 
by visual inspection of the plotted LRR data for cases which the CBS algorithm missed (nine cases) improved 
concordance to 99% reducing the number of discordant calls to 16 (Table 1). Discordant calls were classified into 
one of five categories: (i) no SNP array probes covering the abnormality – meaning that due to the array design 
it was impossible to make a call (n = 5). (ii) MLPA result was informed by a single MLPA probe (n = 2). (iii) The 
CBS algorithm failed to pick up a small focal abnormality, which could be called visually by inspection of the LRR 
data, such that they would be concordant with the MLPA calls (n = 9). (iv) The two techniques disagreed despite 
sufficient probe coverage (n = 6). (v) SNP6.0 detected an abnormality which could not be detected by MLPA due 
to lack of probe coverage (n = 3). Table 2 shows the discordant calls on a case-by-case basis, using both the man-
ually augmented and fully automated CBS calling methods. Figure 1 shows examples of typical concordant and 
discordant profiles for each of the five categories.
MLPA and SNP6.0 probe locations. For the genes represented in the P335 MLPA kit, we investigated 
the precise location of MLPA probes in comparison to the SNP6.0 probes in order to determine whether their 
positioning may explain any of the observed differences in calls. The top scoring BLAT21 alignment for each 
probe uniquely located each probe sequence (provided by MRC Holland, Amsterdam, The Netherlands) to a 
single fully aligned region of the genome without gaps. The co-ordinates of the aligned MLPA probe locations are 
given in Supplementary Table S3 and plotted in Figs. 2 and 3. Most of the genes targeted by the MLPA kit were 
well covered by probes on the SNP6.0 array. However, a few genes had poor probe coverage on the SNP6.0 array: 
CDKN2A lacked probes internal to the gene; while the genes CRLF2/CSF2RA/IL3RA within the PAR1 region 
were covered by a single probe. The MLPA kit had been designed specifically to detect copy number events within 
these genes, hence the probes were well positioned within the exons. However, not every exon of every gene was 
covered, as is the case in RB1, EBF1 and PAX5. The partial coverage of EBF1 and PAX5 resulted in MLPA missing 
three small deletions, which were detected by SNP6.0. These three cases are illustrated in Fig. 1(B) (EBF1) and 
Fig. 4 (PAX5). CDKN2B was also only covered by a single MLPA probe covering exon 1. Issues arising from these 
differences in coverage are discussed in the next section.
Examination of discordant calls. Of the 25 discordant calls made by the SNP6.0 pipeline using the CBS 
algorithm, subsequent manual examination of the LRR data plots produced by DNACopy for these calls revealed 
that nine of the abnormalities were visible by eye but had evaded detection by the CBS algorithm (disagreement 
category iii). Manual inspection of LRR plots in these nine cases allowed for concordant deletion of these oth-
erwise missed abnormalities, eight in IKZF1 and one in PAX5. For the IKZF1 gene, 21/29 deletions were called, 
with eight deletions missed by the CBS algorithm but visible in the LRR data plots, in seven out of these eight 
cases, IKZF1 deletions spanned exons 4 to 7/8. In these cases, the CBS algorithm failed to call focal abnormalities 
which flanked a region of the IKZF1 gene, where there was no probe coverage within intron 3 (between exons 3 
and 4, ~42Kb in length) on the SNP6.0 platform. It should be noted that all array platforms lack coverage of this 
region of IKZF1, due to the repetitive nature of the reference genome sequence of this region and the inability of 
array platforms to target probes complementary to this region in a sequence-specific way. In these cases, visual 
inspection allowed for manual calling of the abnormality; an example of an event downstream of the “IKZF1 hole” 
missed by the CBS algorithm is shown in Fig. 1(C). Here the black line indicates that segmentation is normal, 
but LRR data points reveal a deletion concordant with MLPA data. A further two cases of exon 4–5 and exon 4–8 
deletions were successfully detected by CBS, so whilst it was possible to detect these deletions, the presence of a 
gap in coverage spanning exons 3–4 clearly presents problem for the CBS algorithm when dealing with events 
The grey dotted box shows the extents of CDKN2A in which no SNP6.0 LRR data points can be found. (E) 
An example of a case in which the two techniques disagree (discordance category iv). MLPA shows a deletion 
in two MLPA probes within exon 1 of ETV6, no concordant deflection of the SNP6.0 LRR scatter around the 
copy number normal log2 value of zero is observed. (F) Observation from a single MLPA probe which covers 
CDKN2B and indicates a loss, no concordant shifts can be seen in the LRR values of many SNP6.0 probes.
6Scientific RepoRtS |           (2020) 10:45  | https://doi.org/10.1038/s41598-019-56972-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
immediately upstream of the gap. This issue was easily surmounted by manually inspecting plotted LRR data for 
the IKZF1 gene.
A single gain within PAX5 was missed by the CBS algorithm. It was highly focal and evidenced by a single 
probe, which showed a clearly distinct LRR value of ~1.5. Given the gain was only identified by one probe, it 
would be impossible and unwise for an automated method to call. We employed a minimum number of markers 
cut-off of five for the CBS algorithm in our study, meaning that for an event to be detected at least five probes must 
be involved with a statistically significant deviation. We also tested using a minimum cut-off of four, three and two 
markers; none of these options resulted in any of the nine missed events being called. These missed events were 
not due to the CNA thresholds that we applied over the top of the segmentation data, used to enable categorical 
Figure 2. The location of Individual SNP6.0 and MLPA probes. The location of Individual SNP6.0 probes as 
points of Log R Ratio (LRR) are shown in grey verses the MLPA probes as black lines/rectangles for the genes 
(A) IKZF1 (B) CDKN2B (C) ETV6 (D) RB1 (E) CDKN2A (F) BTG1. Exons from genes are plotted as boxes in 
red. MLPA probe sequences were obtained from MRC-Holland and aligned to hg19 using BLAT. Where the 
MLPA probe aligned to more than one region of the genome the top scoring BLAT alignment (without gaps) 
was then chosen as the definitive location for each MLPA probe.
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labelling of gains, amplifications, losses, and deletions (as illustrated in Supplementary Fig. S3). Simply, these 
missed calls occurred because the CBS algorithm did not segment the events.
In the remaining 16 discordant calls, we found that eight calls resulted from design differences in the two plat-
forms, such that abnormalities detected in one could not be observed in the other owing to a lack of probe cover-
age; these cases belonged to disagreement categories (i) SNP6.0 lacking probes, and (v) MLPA lacking probes. For 
category (i) Fig. 1(B) shows an example of a focal deletion within CDKN2A, which was not detectable by SNP6.0 
because no probes lie within the gene itself (Fig. 2(E)); this situation occurred in three cases. We also observed 
this type of discordance in two cases involving the PAR1 region, where the abnormalities occurred in a region 
within CSF2RA/IL3RA, as there are no probes on the array in this area (Fig. 3(C)). Importantly, none of these 
cases (n = 8) reflected a failure of the CBS algorithm to detect the events, they were simply not observable using 
this particular array. The MLPA kit also failed to detect events due to the absence of probes in the appropriate 
region (discordance category v); we observed three cases of this type. The SNP array was able to detect a focal loss 
in EBF1 (Fig. 1(B)). There were also two cases of focal deletions in PAX5 observed on the SNP array that were 
not detected by the MLPA kit. These both occurred in exon 7 of PAX5, which has no coverage by MLPA probes 
(Fig. 3(B)).
It is also worth highlighting that even when abnormalities called by both methods were concordant, the 
SNP6.0 pipeline was able to reveal extra details and events not observable by MLPA. Figure 5 highlights three 
cases of concordant PAX5 calls, which revealed extra levels of detail regarding copy number events by the SNP6.0 
array using our pipeline that were not observable using the MLPA kit.
Figure 3. The location of Individual SNP6.0 and MLPA probes. The location of Individual SNP6.0 probes as 
points of Log R Ratio (LRR) are shown in grey verses the MLPA probes as black lines for the genes (A) EBF1 
(B) PAX5 (C) PAR1 region. Exons from genes are plotted as boxes in red. In (C) the coloured arrows represent 
individual genes. MLPA probe sequences were obtained from MRC-Holland and aligned to hg19 using BLAT, 
the highest scoring alignment with zero gaps was then chosen as the location of each MLPA probe.
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There were two cases where MLPA detected a focal deletion of CDKN2B with just a single probe (type ii). 
Both of these discordant cases occurred within CDKN2B, in which normal values of copy were observed from the 
many SNP6.0 probes in this region. Here we consider the many repeated observations from the array to be the 
most reliable compared to the single observation from the MLPA kit; an example is given in Fig. 1(F), and relative 
probe locations are shown in Fig. 2(B). These two cases illustrate the potential limitation in measuring the copy 
number of a gene using a single probe in the MLPA kit, which is error prone and unreliable (in part due to the 
inability of MLPA probes to tolerate SNPs) versus the multiple observations taken from the SNP6.0 array. For this 
reason, normally ≥2 adjacent MLPA probes are required for calling a copy number alteration19.
We observed only six calls in total where the two techniques were in disagreement and the supporting evi-
dence was not concordant despite sufficient probe coverage, (disagreement category iii). In all these cases, MLPA 
detected an abnormality but there was no obvious or robust deflection of LLR data points by SNP array. In one 
of these cases, FISH data was available for the gene in question (PAX5), which further corroborated the SNP6.0 
call (highlighted in Table 2). In the remaining discordant cases, it was possible that differences in sensitivity of the 
two techniques to sub-clonal events means that events detected by one are not observable by the other. We also 
checked whether any patient samples were repeatedly discordant indicating a sample swap. All discordant cases, 
came from different samples, with the exception of a single CDKN2A and CDKN2B deletion which occurred 
within the same patient (22572). As these two genes are adjacently located, it was likely the same event detected 
by MLPA.
Effect of using SNP6.0 array data with the UKALL-CNA classifier. Previously, we designed4 and 
validated22 a copy number based ALL risk classifier (UKALL-CNA classifier), which segregates patients based 
on the copy number states of the eight genes and the PAR1 region included in the MLPA P335 kit. This classifier 
assigns patients into three groups: good risk (GR), intermediate risk (IR), and poor risk (PR), with significantly 
different outcomes. In this study, we have grouped together the IR and PR group as the major prognostic findings 
from our discovery and validation studies was that B-other-ALL patients with a GR CNA profile had an excellent 
outcome4 and B-other-ALL formed the bulk of this cohort (121/143 cases). We used the same algorithm to seg-
regate 143 samples by UKALL-CNA classifier using both the MLPA CNA calls and our SNP6.0 pipeline with the 
fully automated CBS or manually augmented calls. Using manually augmented calling, 97% (n = 139) of patients 
would have been assigned to the same CNA-risk profile (Table 3). Here four patients with different profiles, were 
assigned to GR using the SNP calls in place of an IR/PR assignment using the original MLPA calls. Using the 
fully automated SNP CBS calls an additional four cases, eight in total were moved from the IR/PR group to GR 
(Table 3). Table 2 shows the changes in UKALL-CNA classifier result for each discordant case.
Discussion
In this study, we have validated the use of SNP arrays to call MLPA defined UKALL-CNA profiles, which have 
been previously validated across several patient cohorts22. We investigated concordance between two different 
techniques: SNP6.0 array and MLPA for the detection of copy number alterations across key genes somatically 
altered in B-ALL. Our aim was to investigate how well SNP arrays perform for risk classification of B-other-ALL 
using the UKALL-CNA classifier4,22 in comparison to the MLPA kit19. These results are important because they 
provide good evidence that the UKALL-CNA profile can be reliably called using a different platform. Hence, 
future protocols, which decide to adopt the UKALL-CNA classifier into their risk stratification algorithm, can be 
Figure 4. PAX5 losses revealed by SNP6.0 in cases missed by MLPA. Patient ID and gene name are shown in 
the title of each plot, individual SNP6.0 data points of Log R Ratio (LRR) are shown in grey, copy number calls 
by the binary segmentation algorithm are shown as black lines. The copy normal LRR value of zero is shown 
as a grey dotted line, exons from genes are plotted as plotted boxes in rainbow colour, and MLPA data points 
converted into the LRR scale are shown as stars. (A,B) both show examples of a missed loss events in PAX5 exon 
7 which could not be called in MLPA owing to a lack of coverage.
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confident that diagnostic laboratories using SNP arrays will be calling the same profile identified by the research 
studies using MLPA. Although we have focussed on validating our own CNA profile using a single MLPA kit 
(P335), this research has implications for other MLPA derived profiles; for example the IKZF1plus profiles recently 
Figure 5. Extra information revealed by SNP6.0 in cases where calls were overall MLPA and SNP6.0 were 
concordant. Patient ID and gene name are shown in the title of each plot, individual SNP6.0 data points of 
Log R Ratio (LRR) are shown in grey, copy number calls by the binary segmentation algorithm are shown as 
black lines. The copy normal LRR value of zero is shown as a grey dotted line, exons from genes are plotted 
as plotted boxes in rainbow colour, and MLPA data points converted into the LRR scale are shown as stars. 
(A) Shows a concordant PAX5 call in this case both techniques reported a deletion, however, the SNP6.0 CBS 
segmentation show a nested deletion event in exons 6–7 which was not detectable using the MLPA kit because 
these exons have no coverage (Fig. 3(B)). (B) Similarly shows a nested deletion of exon 9 in PAX5. (C) Here both 
techniques show a gain, the gain here taking precedence in SNP6.0 as the reported event as it is higher than the 
lowest nested deletion event, (CBS copy number values of 3.6 vs 1.1 respectively). The nested loss here was not 
detectable via MLPA as no probe covers this region, additionally this copy number pattern is characteristic of a 
PAX5 rearrangement which is of diagnostic significance.
Classification using 
SNP manual calling
Classification using 
SNP automated CBS
GR IR/PR GR IR/PR
CNA risk MLPA
GR 64 0 64 0
IR/PR 4 75 8 71
Table 3. Changes in UKALL-CNA classification due to changes in CNA calls between the two techniques. 
Showing both manual calling of otherwise discordant calls in IKZF1 and PAX5 (left) and calling with CBS 
algorithm alone (right). Individual changes in the UKALL-CNA classifier outcome are listed for each patient in 
Table 2.
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defined and validated by the BFM and AEIOP study groups7. SNP arrays are increasingly being used in a diagnos-
tic setting to detect a wide range of losses, gains, and loss of heterozygosity in cancer. This is evidenced by the fact 
that the American College of Medical Genetics and Genomics (ACMG) and the Cancer Genomics Consortium 
(CGC) have issued guidelines for diagnostic laboratories analysing SNP arrays23. Moreover, chromosomal ploidy 
(for example, near-haploidy and low hypodiploidy) and arm-level events normally derived from conventional 
karyotyping are also detectable using SNP arrays which are key in ALL24. As SNP arrays are genome-wide, 
their routine application means that new risk associated CNA events in other genes can be immediately inves-
tigated. Additionally, our SNP6.0 pipeline employs automated copy number calling, using the CBS algorithm16. 
Automated calling via the CBS algorithm has advantages over manual calling, being much quicker, and scaling 
systematically beyond a handful of genes to the whole-genome in an unbiased way, while returning only sta-
tistically significant copy number events17. Our pipeline uses the popular open source packages PennCNV13,14 
and DNACopy16,17 and can be easily replicated elsewhere, additionally, data exported from either Affymetrix 
Genotyping Console / Chromosome Analysis Suite and Illumina Genome Studio can be analysed with these 
tools to yield high quality segmentation via the CBS algorithm. The freely available Nexus Copy Number Plugin 
for Genome Studio also has an implementation of the CBS algorithm, which is usable with Illumina SNP array 
data. The CBS algorithm is also available for CNA calling of high-throughput sequencing data in methods such 
as CNVKit25.
Using our SNP6.0 analysis pipeline, we found 98% concordance between SNP6.0 and MLPA across 1,287 indi-
vidual calls and 99% concordance if we allowed for manual inspection of IKZF1 and PAX5 LRR plots. Of these 16 
remaining discordant calls, only five cases (4%) were undetectable by SNP6.0 owing to design limitations in the 
location of probes.
The UKALL-CNA risk classifier validated in this study is a useful tool to help segregate patients with differen-
tial relapse risk for treatment stratification. Here we have assigned UKALL-CNA profile based risk classification 
using both manual and automated SNP copy number calls for each patient in comparison to the original MLPA 
based classification. We observed a small proportion of patients who would have been assigned to different risk 
groups (3% for manual and 6% for automated calls). Most of the inconsistencies (four out of eight) arose from the 
lack of information due to automatically calling the copy number states of IKZF1. Among those cases where a lack 
of coverage of probes on the array led to three and two events being missed in CDKN2A and PAR1 respectively, 
(disagreement category i in Tables 1 and 2), the resultant differences in UKALL-CNA profile risk classification 
over MLPA informed classification would potentially lead to two patients (included in the four above) being 
assigned to a different CNA risk group.
Our observations have indicated that the SNP6.0 pipeline, employing the CBS algorithm and manually aug-
mented calling for IKZF1, could be used as an alternative to MLPA based copy number detection systems in 
ALL CNA profile based risk classification. It has also highlighted the need to improve CBS based callers in order 
to cope with missing information, such as the “IKZF1 hole” in the SNP6.0 and other array platforms, which is 
also problematic for genomic alignments of high-throughput sequencing data. Finally, we highlight that other 
array-based platforms will require similar scrutiny with respect to probe location and coverage before being 
employed to call profiles derived using targeted copy number analysis techniques like MLPA.
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